On July 13, 2021, Brii Biosciences Biotechnology Co., Ltd., ("Brii Biosciences", 2137. HK), an "innovator in the field of major infectious diseases in the world" and an innovative medicine research and development service provider, successfully landed on the main board market of Hong Kong Stock Exchange. This project is the 13th unprofitable biotechnology company listed in Hong Kong handled by Tian Yuan Law Firm.
Brii Biosciences offered about 111.58 million shares globally, with an issue price of HK $22.25 per share and raised nearly HK $2.5 billion.
Brii Biosciences's entrance fee for new shares subscription (that is, 500 shares) is HK $11,237.11.
Brii Biosciences is a biotechnology company headquartered in the United States and China. With the mission of breaking through innovation and keen insight to meet the most severe public health challenges, Brii Biosciences is committed to promote the treatment of major infectious diseases in China and the world (such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), novel coronavirus pneumonia virus (COVID-19), multi-drug resistance (MDR) or extensive drug resistance (XDR) Gram-negative bacteria infection) and other diseases with great public health burden (such as the treatment of central nervous system (CNS) diseases).
With excellent R&D technology and strategic cooperation arrangement, Brii Biosciences has created more than ten innovative product R&D pipelines in just over three years: its core products are BRII-179 and BRII-835 for hepatitis B virus (HBV) treatment, which have entered the phase II of clinical research; BRII-196 and BRII-198, which are used for the treatment of novel coronavirus pneumonia virus (COVID-19), have entered the clinical stage III. Most of the other innovative R&D pipelines have entered the Phase I stage of clinical research.
According to the data of Jost Sullivan Consulting Company, the Chinese infectious disease drug market is growing strongly, which is expected to increase from US $32.6 billion in 2019 to US $58.2 billion in 2034 (excluding vaccines). The favorable track of the industry will undoubtedly add opportunities to Brii Biosciences.
Brii Biosciences was oversubscribed nearly 300 times during the public offering stage. The strong cornerstone investors team reflected the great recognition of Brii Biosciences by the market and investors.
Brii Biosciences is a typical international new medicine research and development enterprise, with its founder, management and listing team from the United States, China, Southeast Asia, Europe and other countries and regions.
Tian Yuan Law Firm served as the domestic legal adviser of the co-sponsors Morgan Stanley Asia Limited, UBS Securities Hong Kong Limited and the underwriting syndicate in this listing project. Professional and high-quality services were provided by the team meeting the requirements of international work. All members of the team demonstrated their excellent ability and outstanding style to cope with the unique working environment and needs of international projects, which was unanimously praised by all parties in the listed team.
In recent years, Tian Yuan has made outstanding achievements in overseas listing in the fields of medical health and biotechnology. Since 2021 alone, we have assisted Angelalign, Basecare Medical, Adagene Pharmaceutical, Joinn Labs, SciClone Pharmaceuticals and Zhaoke Ophthalmology to successfully list.
The successful listing of Brii Biosciences will further consolidate Tian Yuan's leading position in the industry.